Quick Answer
Passage BIO, Inc. reported Net Income of -$45.52 million for fiscal year 2025.
Passage BIO, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$45.52M +29.7% |
-$64.77M +36.5% |
-$102.06M +25.0% |
-$136.12M +26.6% |
-$185.39M -65.2% |
-$112.23M -145.9% |
| Diluted EPS | -$14.35 +31.8% |
-$21.04 -1031.2% |
-$1.86 +25.6% |
-$2.50 +28.2% |
-$3.48 -19.6% |
-$2.91 |
| Total Assets | $62.28M -39.2% |
$102.41M -32.0% |
$150.54M -38.2% |
$243.55M -31.4% |
$355.08M +8.3% |
$328.01M +83.6% |
| Cash and Equivalents | $46.30M +23.2% |
$37.57M +73.1% |
$21.71M -37.3% |
$34.60M -73.2% |
$128.97M -4.5% |
$135.00M -15.0% |
| Stockholders Equity | $18.75M -69.4% |
$61.26M -45.0% |
$111.28M -44.7% |
$201.37M -36.8% |
$318.66M +4.6% |
$304.71M +641.7% |
| R&D Expense | $23.28M -42.1% |
$40.18M -34.6% |
$61.42M | — | — | — |
| Operating Income | -$49.30M +30.0% |
-$70.40M +35.0% |
-$108.39M +21.7% |
-$138.39M +25.5% |
-$185.73M -64.5% |
-$112.90M -203.6% |
| Shares Outstanding | 3.18M +0.7% |
3.16M -94.2% |
54.94M +0.6% |
54.61M +0.7% |
54.24M +18.9% |
45.61M +962.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$7.75M | +59.9% | +17.4% |
| Diluted EPS | September 30, 2025 | -$2.44 | +60.3% | +17.6% |
| Total Assets | September 30, 2025 | $74.16M | -33.6% | -6.4% |
| Cash and Equivalents | September 30, 2025 | $52.77M | +63.4% | -8.4% |
| Stockholders Equity | September 30, 2025 | $31.12M | -57.2% | -18.7% |
| R&D Expense | September 30, 2025 | $4.31M | -50.2% | -25.9% |
| Operating Income | September 30, 2025 | -$8.65M | +58.2% | +16.2% |
| Shares Outstanding | September 30, 2025 | 3.18M | -94.9% | +0.0% |
- Passage BIO, Inc. reported Net Income of -$45.52 million for fiscal year 2025.
- Passage BIO, Inc. showed an increase of +29.7% in Net Income compared to the prior fiscal year.
- Passage BIO, Inc. reported Diluted EPS of $14.35 per share (loss) for fiscal year 2025.
- Passage BIO, Inc. showed an increase of +31.8% in Diluted EPS compared to the prior fiscal year.
- Passage BIO, Inc. reported Total Assets of $62.28 million for fiscal year 2025.
- Passage BIO, Inc. showed a decrease of -39.2% in Total Assets compared to the prior fiscal year.
- Passage BIO, Inc. reported Cash and Equivalents of $46.30 million for fiscal year 2025.
- Passage BIO, Inc. showed an increase of +23.2% in Cash and Equivalents compared to the prior fiscal year.
- Passage BIO, Inc. reported Stockholders Equity of $18.75 million for fiscal year 2025.
- Passage BIO, Inc. showed a decrease of -69.4% in Stockholders Equity compared to the prior fiscal year.
- Passage BIO, Inc. reported R&D Expense of $23.28 million for fiscal year 2025.
- Passage BIO, Inc. showed a decrease of -42.1% in R&D Expense compared to the prior fiscal year.
- Passage BIO, Inc. reported Operating Income of -$49.30 million for fiscal year 2025.
- Passage BIO, Inc. showed an increase of +30.0% in Operating Income compared to the prior fiscal year.
- Passage BIO, Inc. reported Shares Outstanding of 3.18 million shares for fiscal year 2025.
- Passage BIO, Inc. showed an increase of +0.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: